Analytical Data
-
基因名
p19INK4d
- Application
-
别名
p19-INK4d
-
种属
Human
-
表达系统
E. coli
-
标签
N- GST
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P55273
-
表达区间
1-166aa
-
分子量
44.7 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
P19INK4d, a member of the INK4 family of cyclin-dependent kinase inhibitors, has garnered significant attention in cancer research due to its role in regulating the cell cycle and promoting cellular senescence. Unlike other INK4 proteins, P19INK4d specifically inhibits CDK4 and CDK6, thereby blocking the phosphorylation of retinoblastoma (Rb) protein and preventing the progression from the G1 phase to the S phase of the cell cycle. This mechanism positions P19INK4d as a crucial player in tumor suppression, particularly in tumors that exhibit alterations in the Rb pathway. Moreover, its expression is often found to be downregulated in various malignancies, leading researchers to explore its potential as a therapeutic target for cancer treatment. Understanding the functional dynamics of P19INK4d, including its interactions with other cell cycle regulators and its influence on cellular senescence, can provide insights into novel cancer therapies. Additionally, studies of recombinant P19INK4d protein can aid in elucidating its molecular mechanisms and determining its efficacy in different cancer models, potentially leading to the development of innovative strategies to reactivate its tumor-suppressive functions in malignancies characterized by its loss or downregulation. Thus, ongoing research into P19INK4d not only enhances our understanding of tumor biology but also holds promise for the advancement of cancer therapeutics.
